Restructuring (Tables)

9 Months Ended

Sep. 29, 2017

Restructuring and Related Activities [Abstract]

Schedule of Restructuring Reserve by Type of Cost

The restructuring, impairment and other related charges incurred during the nine-month period ended September 29, 2017 related to the discontinued product line in the Diagnostics segment are reflected in the following captions in the accompanying Consolidated Condensed Statement of Earnings ($ in millions):

Cost of sales	$	20.7
Selling, general and administrative expenses	55.2
Total	$	75.9